LHYFE Fundamental Analysis - LHYFE SAS

Name: LHYFE SAS (LHYFE) Stock
Brand: LHYFE SAS
Rating: 5.5 (3 reviews)

Fundamental Rating

Taking everything into account, LHYFE scores 3 out of 10 in our fundamental rating. LHYFE was compared to 61 industry peers in the Oil, Gas & Consumable Fuels industry. LHYFE has a bad profitability rating. Also its financial health evaluation is rather negative. LHYFE is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

LHYFE had negative earnings in the past year.

In the past year LHYFE has reported a negative cash flow from operations.

In the past 5 years LHYFE always reported negative net income.

In the past 5 years LHYFE always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -15.49%, LHYFE is not doing good in the industry: 90.16% of the companies in the same industry are doing better.

Looking at the Return On Equity, with a value of -72.30%, LHYFE is doing worse than 90.16% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-15.49%
ROE	-72.3%
ROIC	N/A

ROA(3y)-14.91%

ROA(5y)-15.02%

ROE(3y)-30.83%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LHYFE has a better Gross Margin (80.73%) than 85.25% of its industry peers.

LHYFE's Gross Margin has improved in the last couple of years.

LHYFE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	80.73%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y97.82%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LHYFE does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for LHYFE remains at a similar level compared to 1 year ago.

LHYFE has more shares outstanding than it did 5 years ago.

The debt/assets ratio for LHYFE is higher compared to a year ago.

2.2 Solvency

LHYFE has an Altman-Z score of -0.46. This is a bad value and indicates that LHYFE is not financially healthy and even has some risk of bankruptcy.

LHYFE has a Altman-Z score of -0.46. This is amonst the worse of the industry: LHYFE underperforms 83.61% of its industry peers.

A Debt/Equity ratio of 1.55 is on the high side and indicates that LHYFE has dependencies on debt financing.

The Debt to Equity ratio of LHYFE (1.55) is worse than 85.25% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.55
Debt/FCF	N/A
Altman-Z	-0.46

ROIC/WACCN/A

WACC7.64%

2.3 Liquidity

A Current Ratio of 1.69 indicates that LHYFE should not have too much problems paying its short term obligations.

The Current ratio of LHYFE (1.69) is better than 67.21% of its industry peers.

A Quick Ratio of 1.68 indicates that LHYFE should not have too much problems paying its short term obligations.

With a decent Quick ratio value of 1.68, LHYFE is doing good in the industry, outperforming 75.41% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.69
Quick Ratio	1.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for LHYFE have decreased strongly by -16.57% in the last year.

LHYFE shows a strong growth in Revenue. In the last year, the Revenue has grown by 209.99%.

Measured over the past years, LHYFE shows a very strong growth in Revenue. The Revenue has been growing by 195.81% on average per year.

EPS 1Y (TTM)-16.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-55.16%

Revenue 1Y (TTM)209.99%

Revenue growth 3Y195.81%

Revenue growth 5YN/A

Sales Q2Q%177.45%

3.2 Future

The Earnings Per Share is expected to grow by 27.21% on average over the next years. This is a very strong growth

LHYFE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 129.95% yearly.

EPS Next Y10.59%

EPS Next 2Y30.15%

EPS Next 3Y27.21%

EPS Next 5YN/A

Revenue Next Year98.42%

Revenue Next 2Y290.88%

Revenue Next 3Y211.27%

Revenue Next 5Y129.95%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LHYFE. In the last year negative earnings were reported.

Also next year LHYFE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

LHYFE's earnings are expected to grow with 27.21% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.15%

EPS Next 3Y27.21%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LHYFE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LHYFE SAS

EPA:LHYFE (10/28/2025, 1:57:16 PM)

3.068

+0.01 (+0.26%)

Chartmill FA Rating

GICS SectorEnergy

GICS IndustryGroupEnergy

GICS IndustryOil, Gas & Consumable Fuels

Earnings (Last)09-30 2025-09-30

Earnings (Next)N/A N/A

Inst Owners8.93%

Inst Owner ChangeN/A

Ins Owners21.32%

Ins Owner ChangeN/A

Market Cap147.51M

Revenue(TTM)8.07M

Net Income(TTM)-36790000

Analysts84

Price Target4.79 (56.13%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-6.47%

PT rev (3m)-7.84%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)10.12%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-55.7%

Revenue NY rev (3m)-56.39%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	18.29
P/FCF	N/A
P/OCF	N/A
P/B	2.9
P/tB	4.88
EV/EBITDA	N/A

EPS(TTM)-0.77

EYN/A

EPS(NY)-0.24

Fwd EYN/A

FCF(TTM)-1.14

FCFYN/A

OCF(TTM)-0.48

OCFYN/A

SpS0.17

BVpS1.06

TBVpS0.63

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-15.49%
ROE	-72.3%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	80.73%
FCFM	N/A

ROA(3y)-14.91%

ROA(5y)-15.02%

ROE(3y)-30.83%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y97.82%

GM growth 5YN/A

F-Score4

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	1.55
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	483.84%
Cap/Sales	391.28%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.69
Quick Ratio	1.68
Altman-Z	-0.46

F-Score4

WACC7.64%

ROIC/WACCN/A

Cap/Depr(3y)957.78%

Cap/Depr(5y)2682.27%

Cap/Sales(3y)1925.18%

Cap/Sales(5y)13341.9%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-16.57%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-55.16%

EPS Next Y10.59%

EPS Next 2Y30.15%

EPS Next 3Y27.21%

EPS Next 5YN/A

Revenue 1Y (TTM)209.99%

Revenue growth 3Y195.81%

Revenue growth 5YN/A

Sales Q2Q%177.45%

Revenue Next Year98.42%

Revenue Next 2Y290.88%

Revenue Next 3Y211.27%

Revenue Next 5Y129.95%

EBIT growth 1Y-10.05%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year34.47%

EBIT Next 3Y36.05%

EBIT Next 5Y27.12%

FCF growth 1Y-63.79%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-20.98%

OCF growth 3YN/A

OCF growth 5YN/A

LHYFE SAS / LHYFE.PA FAQ

Can you provide the ChartMill fundamental rating for LHYFE SAS?

ChartMill assigns a fundamental rating of 3 / 10 to LHYFE.PA.

Can you provide the valuation status for LHYFE SAS?

ChartMill assigns a valuation rating of 1 / 10 to LHYFE SAS (LHYFE.PA). This can be considered as Overvalued.

What is the profitability of LHYFE stock?

LHYFE SAS (LHYFE.PA) has a profitability rating of 1 / 10.

What is the financial health of LHYFE SAS (LHYFE.PA) stock?

The financial health rating of LHYFE SAS (LHYFE.PA) is 2 / 10.

LHYFE SAS (LHYFE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

LHYFE SAS / LHYFE.PA FAQ

Can you provide the ChartMill fundamental rating for LHYFE SAS?

Can you provide the valuation status for LHYFE SAS?

What is the profitability of LHYFE stock?

What is the financial health of LHYFE SAS (LHYFE.PA) stock?